Research Use Only (RUO). This article is for education and shares what published science says about a research compound. It is not medical advice, and nothing here is a suggestion to use any peptide on people or animals.
Searching retatrutide vs tirzepatide, tirzepatide vs retatrutide, or reta vs tirz? Here is a simple, research-based comparison of these two metabolic peptides. This is educational; both are handled here as Research Use Only reference materials.
The core difference: three targets vs two
Tirzepatide is a dual agonist. It acts on two receptors: GLP-1 and GIP. Retatrutide is a triple agonist. It acts on those two plus a third, the glucagon receptor. That extra glucagon action is the main reason researchers study retatrutide as a separate compound.
What the trials reported
In its Phase 2 trial, retatrutide showed mean weight reductions of up to 24.2% at 48 weeks, and Phase 3 TRIUMPH reports reached roughly 28-30%. Tirzepatide, in its SURMOUNT-1 Phase 3 trial, reported mean reductions around 20.9% at the top dose. These figures come from separate trials with different designs, so they are not a head-to-head result, but they show why both draw research interest.
Approval status
Tirzepatide is already an approved medicine in some uses. Retatrutide is not FDA approved and remains in Phase 3 trials as of 2026. For research buyers, both are sold as reference compounds, not medicines.
Which do researchers choose?
It depends on the research question. A study focused on the added glucagon pathway points toward retatrutide; a study on the established dual-agonist mechanism points toward tirzepatide. Many labs keep both on hand for comparison work.
Retatrutide research materials at Dissolv Labs
Dissolv Labs supplies high-purity compounds as reference materials for laboratory research only. They are not for human or animal use.
Frequently asked questions
Is retatrutide stronger than tirzepatide?
Trial reports show larger mean weight reductions for retatrutide, but these are separate trials, not a direct comparison.
What is reta vs tirz in one line?
Reta (retatrutide) is a triple agonist; tirz (tirzepatide) is a dual agonist.
Is retatrutide the same as Mounjaro?
No. Mounjaro is a brand of tirzepatide. Retatrutide is a different, investigational compound.
The bottom line
Retatrutide adds a third (glucagon) target to the dual action of tirzepatide, and its trials report larger mean weight changes - but it is still investigational, while tirzepatide is further along. Both are Research Use Only here.
Sources
- Jastreboff et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (NEJM, via PubMed)
- Eli Lilly: Retatrutide Phase 3 (TRIUMPH) topline results
- Tirzepatide SURMOUNT-3 Phase 3 trial (PMC)
- Drugs.com: Retatrutide history and FDA approval status
Disclaimer: All Dissolv Labs products are sold for Research Use Only and are not for human or veterinary use. This content is educational and is not medical advice, diagnosis, treatment guidance, or a recommendation to consume any substance.
